Gene Test Distinguishes Kawasaki Disease from Other Illnesses
By LabMedica International staff writers Posted on 13 Aug 2018 |
Image: A test incorporating the 13-transcripts might enable earlier diagnosis and treatment of Kawasaki Disease (Photo courtesy of the University of California, San Diego and Imperial College London).
Kawasaki disease (KD), the most common acquired heart disease in children, can be diagnosed using a blood test that measures a 13-transcript gene expression signature.
Currently there are no simple diagnostic tests for Kawasaki disease. To correct this lack, investigators at the University of California San Diego (USA), Imperial College London (United Kingdom) and a group of international collaborators explored the use of whole-blood gene expression patterns to distinguish KD from other childhood infectious and inflammatory conditions.
To this end, the investigators carried out a case-control study comprising a discovery group that included training and test sets and a validation group of children with KD or comparator febrile illness. The setting was pediatric centers in the United Kingdom, Spain, the Netherlands, and the United States. The training and test discovery group comprised 404 children with infectious and inflammatory conditions (78 KD, 84 other inflammatory diseases, and 242 bacterial or viral infections) and 55 healthy controls. The independent validation group comprised 102 patients with KD, including 72 in the first seven days of illness, and 130 febrile controls. Whole-blood gene expression was evaluated using microarrays, and minimal transcript sets distinguishing KD were identified using a novel variable selection method.
Results revealed that a 13-transcript signature identified in the discovery training set distinguished KD from other infectious and inflammatory conditions in the discovery test set.
"A 13-transcript blood gene expression signature distinguished KD from the range of infectious and inflammatory conditions with which it is often clinically confused," said contributing author Dr. Jane C. Burns, director of the Kawasaki disease research center at the University of California, San Diego. "A test incorporating the 13-transcripts might enable earlier diagnosis and treatment of KD, preventing cardiac complications and reducing inappropriate treatment in those with other diseases. Our findings represent a step toward better diagnosis based on molecular signatures rather than clinical criteria."
"As there is no diagnostic test for Kawasaki disease, late diagnosis often results in delayed or missed treatment and an increased risk of coronary artery aneurysms," said Dr. Burns. "We sought to identify a whole blood gene expression signature that distinguishes children with KD in the first week of illness."
The study was published in the August 6, 2018, online edition of the journal JAMA Pediatrics.
Related Links:
University of California San Diego
Imperial College London
Currently there are no simple diagnostic tests for Kawasaki disease. To correct this lack, investigators at the University of California San Diego (USA), Imperial College London (United Kingdom) and a group of international collaborators explored the use of whole-blood gene expression patterns to distinguish KD from other childhood infectious and inflammatory conditions.
To this end, the investigators carried out a case-control study comprising a discovery group that included training and test sets and a validation group of children with KD or comparator febrile illness. The setting was pediatric centers in the United Kingdom, Spain, the Netherlands, and the United States. The training and test discovery group comprised 404 children with infectious and inflammatory conditions (78 KD, 84 other inflammatory diseases, and 242 bacterial or viral infections) and 55 healthy controls. The independent validation group comprised 102 patients with KD, including 72 in the first seven days of illness, and 130 febrile controls. Whole-blood gene expression was evaluated using microarrays, and minimal transcript sets distinguishing KD were identified using a novel variable selection method.
Results revealed that a 13-transcript signature identified in the discovery training set distinguished KD from other infectious and inflammatory conditions in the discovery test set.
"A 13-transcript blood gene expression signature distinguished KD from the range of infectious and inflammatory conditions with which it is often clinically confused," said contributing author Dr. Jane C. Burns, director of the Kawasaki disease research center at the University of California, San Diego. "A test incorporating the 13-transcripts might enable earlier diagnosis and treatment of KD, preventing cardiac complications and reducing inappropriate treatment in those with other diseases. Our findings represent a step toward better diagnosis based on molecular signatures rather than clinical criteria."
"As there is no diagnostic test for Kawasaki disease, late diagnosis often results in delayed or missed treatment and an increased risk of coronary artery aneurysms," said Dr. Burns. "We sought to identify a whole blood gene expression signature that distinguishes children with KD in the first week of illness."
The study was published in the August 6, 2018, online edition of the journal JAMA Pediatrics.
Related Links:
University of California San Diego
Imperial College London
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans